CureVac Says Pivotal Phase 2B/3 In Europe And Latin America Fully Recruited With Over 40,000 Participants, Interim Analysis For Efficacy Expected In Q2 2021; Reiterates Expects To Manufacture Up To 300M Doses Of CVnCoV By End Of 2021 And Up To 1B In 2022